Premium
Indications and immediate and long‐term results of a novel pericardium covered stent graft: Consecutive 5 year single center experience
Author(s) -
Secco Gioel Gabrio,
Serdoz Roberta,
Kilic Ismail Dogu,
Caiazzo Gianluca,
Mattesini Alessio,
Parisi Rosario,
De Luca Giuseppe,
Pistis Gianfranco,
Marino Paolo Nicola,
Di Mario Carlo
Publication year - 2016
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.26131
Subject(s) - medicine , restenosis , surgery , stent , myocardial infarction , stenosis , mace , percutaneous coronary intervention , timi , pericardium , radiology , cardiology
Background The use of covered stent grafts during percutaneous coronary intervention (PCI) is a life saving solution to seal acute iatrogenic vessel rupture. However, the presence of an impenetrable mechanical barrier is also appealing during treatment of friable coronary plaques but the synthetic PTFE‐membrane that might trigger excessive neointimal proliferation has limited its elective‐use. Pericardium tissue may offer an appealing “natural” alternative. Aim of our study is to report the consecutive 5‐year single center experience with the use of pericardium‐covered stents (PCS) (ITGI‐Medical, Israel) in a variety of emergency and elective applications. Methods Nineteen consecutive patients undergoing implantation of PCS at the Royal Brompton in the last 5‐years. Reasons for PCS implantation included treatment of degenerated vein grafts, large coronary aneurysms, and acute iatrogenic vessel rupture. Results Angiographic success, defined as the ability of the device to be deployed in the indexed lesion with no contrast extravasation with residual angiographic stenosis <30% and a final thrombolysis in myocardial infarction (TIMI)‐3 flow was achieved in all cases. Procedural success, defined as the achievement of angiographic success without any major adverse cardiovascular event (MACE) was achieved in 94.7% of patients. In‐stent restenosis (ISR) was observed in 26.3% and all patients underwent successful target vessel revascularization with DES (mean time to restenosis 9.0 ± 4.0 months). At a mean follow‐up of 32.5 ± 23.3 months no acute or late stent thrombosis was observed. Conclusion PCSs were effective in the treatment of friable embolization‐prone coronary plaques, sealing of acute iatrogenic vessel rupture and exclusion of large aneurysms with no thrombosis but high target lesion revascularization. © 2015 Wiley Periodicals, Inc.